Release date: 8 October 2010
Promoter – Financial Intermediary
Novozymes A/S
Location
Description
The project concerns the European-based part of the promoter’s corporate RDI programme in the period 2010-2011 related to discovery and development of innovative enzymes, novel pharmaceutical proteins, and micro-organisms.
Objectives
The R&D investments focus on improving current products and processes as well as developing new business opportunities. The project is expected to safeguard and enhance the leading competitive position of an EU knowledge-based, R&D-driven enterprise
Sector(s)
Proposed EIB finance (Approximate amount)
EUR 60 million.
Total cost (Approximate amount)
EUR 240 million.
Environmental aspects
The project concerns investment in research and development activities that are expected to be carried out in existing R&D facilities, in which case an EIA should not be required according to Directive 85/337/EC and its amending Directives. However the promoter will be required to ensure that the provisions of the EIA Directive and those of any other relevant environmental acquis are complied with. Full environmental details will be assessed during the appraisal.
Procurement
The promoter is a private company not operating in the Utilities sector, and is thus not covered by EU Directives on procurement. The promoter has sound procedures for procuring specialized equipment and external services and the R&D activities are carried out by internal research staff hence they are expected to be entirely appropriate to the industry and satisfactory to the Bank.
Status
Signed - 10/12/2010
Disclaimer
Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).